Denosumab
- Generic Name
- Denosumab
- Brand Names
- Prolia, Xgeva, Wyost, Jubbonti
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 615258-40-7
- Unique Ingredient Identifier
- 4EQZ6YO2HI
- Background
Denosumab is a novel, fully human IgG2 monoclonal antibody specific to receptor activator of nuclear factor kappa-B ligand (RANKL), suppresses bone resorption markers in patients with a variety of metastatic tumors and is being investigated in multiple clinical trials for the prevention and treatment of bone metastases. Chemically, it consists of 2 heavy and...
- Indication
Prolia is indicated for the treatment of postmenopausal women with osteoporosis at high risk for fracture. It reduces the incidence of vertebral, nonvertebral, and hip fractures. Prolia is also indicated as a treatment to increase bone mass in women at high risk for fracture receiving adjuvant aromatase inhibitor therapy for breast cancer. It can also be use...
- Associated Conditions
- Bone Fractures, Bone Giant Cell Tumor, Bone Loss, Bone pain, Spinal Cord Compression, Bone destruction, High risk of fracture Osteoporosis, Refractory Hypercalcemia of malignancy
- Associated Therapies
- -
Study of the Key Techniques of Prevention and Treatment of Osteoporotic Refracture
- Conditions
- Interventions
- First Posted Date
- 2023-05-19
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 2478
- Registration Number
- NCT05866029
- Locations
- 🇨🇳
Beijing Friendship Hospital, Capital Medical University, Beijing, China
🇨🇳Beijing Hospital, Beijing, China
🇨🇳Beijing Pinggu Hospital, Beijing, China
A Study to Evaluate the Efficacy and Safety of Narlumosbart (JMT103) in Patients With Giant Cell Tumor of Bone
- Conditions
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2023-04-19
- Lead Sponsor
- Shanghai JMT-Bio Inc.
- Target Recruit Count
- 146
- Registration Number
- NCT05813665
- Locations
- 🇨🇳
Beijing Ji Shui Tan Hospital, Beijing, Beijing, China
Osseointegrated Transdermal Femoral Amputation Prostheses
- Conditions
- Interventions
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-04-21
- Lead Sponsor
- University of Aarhus
- Target Recruit Count
- 6
- Registration Number
- NCT05736640
Denosumab Treatment in CKD Patients at High Risk of Fracture
- Conditions
- Interventions
- First Posted Date
- 2023-01-20
- Last Posted Date
- 2023-01-25
- Lead Sponsor
- Capital Medical University
- Target Recruit Count
- 102
- Registration Number
- NCT05692297
- Locations
- 🇨🇳
Nephrology Department of Beijing Jishuitan Hospital, Beijing, Beijing, China
Muscle Impact of Treating Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2022-12-27
- Last Posted Date
- 2024-02-09
- Lead Sponsor
- Nami Safai Haeri
- Target Recruit Count
- 20
- Registration Number
- NCT05666310
- Locations
- 🇺🇸
University of Pittsburgh, Pittsburgh, Pennsylvania, United States
Denosumab vs Alendronate After Vertebroplasty
- Conditions
- Interventions
- First Posted Date
- 2022-12-22
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Shenzhen People's Hospital
- Target Recruit Count
- 90
- Registration Number
- NCT05662358
- Locations
- 🇨🇳
Shenzhen People's Hospital, Shenzhen, Guangdong, China
Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease
- Conditions
- Interventions
- First Posted Date
- 2022-08-09
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Aristotle University Of Thessaloniki
- Target Recruit Count
- 70
- Registration Number
- NCT05493761
- Locations
- 🇬🇷
1st Department of Obstetrics and Gynecology, School, of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
🇬🇷Department of Endocrinology, "Hippokration" General Hospital of Thessaloniki, Thessaloníki, Greece
🇬🇷424 General Military Hospital, Thessaloníki, Greece
PraG With RANKL Inhibitor for the Treatment of Advanced Multiple Metastatic Solid Tumors
- First Posted Date
- 2022-06-28
- Last Posted Date
- 2022-08-18
- Lead Sponsor
- Second Affiliated Hospital of Soochow University
- Target Recruit Count
- 51
- Registration Number
- NCT05435768
- Locations
- 🇨🇳
The Second Affiliated Hospital of Soochow University, Suzhou, Jiangsu, China
Denosumab Biosimilar Injection in Post Menopausal Women With Osteoporosis
- Conditions
- Interventions
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2023-10-13
- Lead Sponsor
- Lambda Therapeutic Research Ltd.
- Target Recruit Count
- 552
- Registration Number
- NCT05419427
- Locations
- 🇮🇳
S. R. Kalla Memorial Gastro & General Hospital, Jaipur, Rajasthan, India
Study of Denosumab for Prevention of Skeletal Disease Progression in Children With Fibrous Dysplasia
- First Posted Date
- 2022-06-15
- Last Posted Date
- 2024-06-17
- Target Recruit Count
- 15
- Registration Number
- NCT05419050
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.